BLAU3 Stock Overview
Blau Farmacêutica S.A., a pharmaceutical company provides private label drugs in Brazil, Argentina, Colombia, the United States, Ecuador, Peru, and Uruguay.
Blau Farmacêutica S.A. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||R$16.04|
|52 Week High||R$31.48|
|52 Week Low||R$14.18|
|1 Month Change||-0.93%|
|3 Month Change||-9.22%|
|1 Year Change||-44.01%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-60.97%|
Recent News & Updates
What Does The Future Hold For Blau Farmacêutica S.A. (BVMF:BLAU3)? These Analysts Have Been Cutting Their EstimatesMay 14
Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen NextFeb 24
Getting In Cheap On Blau Farmacêutica S.A. (BVMF:BLAU3) Is UnlikelyOct 14
Robust Earnings May Not Tell The Whole Story For Blau Farmacêutica (BVMF:BLAU3)Aug 17
|BLAU3||BR Biotechs||BR Market|
Return vs Industry: BLAU3 underperformed the BR Biotechs industry which returned -8.1% over the past year.
Return vs Market: BLAU3 underperformed the BR Market which returned 6.5% over the past year.
|BLAU3 Average Weekly Movement||7.0%|
|Biotechs Industry Average Movement||9.0%|
|Market Average Movement||5.2%|
|10% most volatile stocks in BR Market||8.9%|
|10% least volatile stocks in BR Market||2.6%|
Stable Share Price: BLAU3 is more volatile than 75% of BR stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: BLAU3's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of BR stocks.
About the Company
Blau Farmacêutica S.A., a pharmaceutical company provides private label drugs in Brazil, Argentina, Colombia, the United States, Ecuador, Peru, and Uruguay. The company’s medications cover various therapeutic classes, such as immunology, hematology, oncology, nephrology, specialties, and antibiotics. It also offers biological drugs; oral and injectable drugs for treating cancer; specialized treatments for infectious diseases; and prescription and non-prescription drugs, including dermo-medicines, condoms, and others for retail and non-retail markets.
Blau Farmacêutica S.A. Fundamentals Summary
|BLAU3 fundamental statistics|
Is BLAU3 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BLAU3 income statement (TTM)|
|Cost of Revenue||R$819.77m|
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
|Earnings per share (EPS)||1.78|
|Net Profit Margin||23.46%|
How did BLAU3 perform over the long term?See historical performance and comparison